title: [Evaluation of progression-free interval in patients with ovarian cancer treated by first-line chemotherapy with paclitaxel and carboplatin].
abstract: Combination therapy with paclitaxel is widely proposed for first-line adjuvant treatment in ovarian cancer patients in Hungary as well as worldwide. The authors summarize the results of paclitaxel-carboplatin therapy of the years from 2000 to 2002, and compare them to the results observed in 2002.
  
  
  METHODS
  86 patients with ovarian cancer of stage I-IV were treated with the combination with paclitaxel (175 mg/m2, 3 hours) and carboplatin (AUC 5) at the Gynecological Department, National Institute of Oncology, Budapest. Average age of the patients was found 54+/-9.8 years. Optimal surgery (hysterectomy with bilateral adnexectomy and omentectomy with a maximal residual tumor burden of 1 cm) was done in 43 of the 86 patients.
  
  
  RESULTS
  Tumor-free status was found in 60% and 31% of the patients in 2002 and 2005 respectively. Tumor-free status was observed in the groups of optimally operated and non-optimally operated patients in 79% and 42% in 2002 and in 44% and 19% in 2005. Median progression-free interval was higher in the optimally than in the nonoptimally operated patients (25 and 11 months), and was resulted in 16.5 months of all patients.
  
  
  CONCLUSIONS
  Our paclitaxel-carboplatin treatment resulted in a similar progression-free interval as that was found in the literature, however, the ratio of tumor-free patients decreased to 31% during the follow-up time (median: 41 months).
authors.affiliation: Nogyógyászati Osztály, Országos Onkológiai Intézet, Budapest, 1122.
authors.forename: Ottó
authors.initials: O
authors.lastname: Lehoczky
authors.forename: Tamás
authors.initials: T
authors.lastname: Pulay
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel